BrightInsight has raised $13 million in funding to accelerate the development of its AI-enabled medication persistence and adherence solutions and scale patient support programs globally. The San Jose-based digital health company said the round included both existing and new backers: Eclipse, General Catalyst, Insight Partners, Mayo Clinic, and New Leaf Venture Partners.
The company positioned the financing around the persistent problem of medication non-adherence, citing research that adherence rates for chronic diseases often sit around 50% and linking non-adherence to significant clinical and economic consequences, including avoidable hospitalizations and costs in the U.S. BrightInsight said it aims to address the gap between prescription and long-term persistence through compliant, cloud-based digital health tools used by biopharma companies.
BrightInsight said the new capital will help it incorporate AI “end-to-end” across its product roadmap, including generating user-specific insights and predictions such as medication churn. The company also plans to broaden its disease-specific partner ecosystem and extend its platform to support additional stakeholders, including caregivers and nurse educators.
BrightInsight highlighted its collaboration work on patient support initiatives, including the Patient App tied to its work with Sanofi and Regeneron, which it said it plans to scale across a broader range of diseases and therapies. The company also pointed to program engagement metrics it says it typically observes across deployments, with 30% to 70% of invited patients participating and a similar share still using the solution one year later.
KEY QUOTES:
“We typically see 30-70% or more of invited patients participating in our deployed programs, with a similar percentage of those patients continuing to use the solutions one year later. Further, we are seeing these results across various diseases and patient populations.”
Kal Patel, CEO & Co-Founder, BrightInsight
“Having been an early supporter of BrightInsight, it has been remarkable to watch the company’s evolution and the team’s disciplined execution to tackle this global patient challenge. Our decision to participate in this latest round was driven by the clear, measurable impact BrightInsight is already delivering in the patient support landscape. The Company has proven they can scale a platform that solves a critical market need, and we are proud to increase our commitment as they enter this next phase of growth.”
Vijay Lathi, Managing Director, New Leaf Venture Partners
“Patient engagement and medication adherence remain some of the most stubborn challenges in healthcare. The unique, real-world data generated on the BrightInsight platform is transforming how therapies are supported. By combining that data with advanced AI, we can better predict medication churn and deliver personalized interventions that help patients stay on therapy and achieve better outcomes.”
Robert Zdon, Chief Operating Officer, BrightInsight
